These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 28216276)

  • 41. Prognostic Utility of Parameters Derived From Pretreatment Dual-Layer Spectral-Detector CT in Patients With Metastatic Renal Cell Carcinoma.
    Drljevic-Nielsen A; Donskov F; Mains JR; Andersen MB; Thorup K; Thygesen J; Rasmussen F
    AJR Am J Roentgenol; 2022 May; 218(5):867-876. PubMed ID: 34910540
    [No Abstract]   [Full Text] [Related]  

  • 42. Role of WNT/β-Catenin Pathway as Potential Prognostic and Predictive Factors in Renal Cell Cancer Patients Treated With Everolimus in the Second and Subsequent Lines.
    Bodnar L; Stec R; Cierniak S; Synowiec A; Wcisło G; Jesiotr M; Koktysz R; Chrom P; Szczylik C
    Clin Genitourin Cancer; 2018 Aug; 16(4):257-265. PubMed ID: 29483043
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma.
    Santoni M; De Giorgi U; Iacovelli R; Conti A; Burattini L; Rossi L; Luca Burgio S; Berardi R; Muzzonigro G; Cortesi E; Amadori D; Cascinu S
    Br J Cancer; 2013 Oct; 109(7):1755-9. PubMed ID: 24008663
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of modified Glasgow prognostic score on predicting prognosis and modification of risk model for patients with metastatic renal cell carcinoma treated with first line tyrosine kinase inhibitor.
    Yukihiro K; Teishima J; Goto K; Aoki G; Sekino Y; Hayashi T; Hasegawa Y; Mita K; Kato M; Kajiwara M; Shigeta M; Maruyama S; Kadonishi Y; Fujiwara S; Hinata N
    Urol Oncol; 2022 Oct; 40(10):455.e11-455.e18. PubMed ID: 35851184
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Characteristics of long-term and short-term survivors of metastatic renal cell carcinoma treated with targeted therapies: results from the International mRCC Database Consortium.
    Fay AP; Xie WL; Lee JL; Harshman LC; Bjarnason GA; Knox JJ; Ernst S; Wood L; Vaishamayan UN; Yuasa T; Tan MH; Rha SY; Donskov F; Agarwal N; Kollmannsberger CK; North SA; Rini BI; Choueiri TK; Heng DY
    Clin Genitourin Cancer; 2015 Apr; 13(2):150-5. PubMed ID: 25458371
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Real world prospective experience of axitinib in metastatic renal cell carcinoma in a large comprehensive cancer centre.
    Matias M; Le Teuff G; Albiges L; Guida A; Brard C; Bacciarelo G; Loriot Y; Massard C; Lassau N; Fizazi K; Escudier B
    Eur J Cancer; 2017 Jul; 79():185-192. PubMed ID: 28511146
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cachexia index in predicting outcomes among patients receiving immune checkpoint inhibitor treatment for metastatic renal cell carcinoma.
    Aslan V; Kılıç ACK; Sütcüoğlu O; Eraslan E; Bayrak A; Öksüzoğlu B; Tahtacı G; Özdemir N; Üner A; Günel N; Özet A; Yazıcı O
    Urol Oncol; 2022 Nov; 40(11):494.e1-494.e10. PubMed ID: 36137881
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell Carcinoma.
    De Velasco G; Xie W; Donskov F; Albiges L; Beuselinck B; Srinivas S; Agarwal N; Lee JL; Brugarolas J; Wood LA; Rha SY; Kollmannsberger C; North S; Kanesvaran R; Rini BI; Broom R; Yamamoto H; Kaymakcalan MD; Heng DYC; Choueiri TK
    Clin Genitourin Cancer; 2017 Jun; 15(3):403-410.e2. PubMed ID: 28254206
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Validation of the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: the Spanish Oncologic Genitourinary Group (SOGUG) SPAZO study.
    Pérez-Valderrama B; Arranz Arija JA; Rodríguez Sánchez A; Pinto Marín A; Borrega García P; Castellano Gaunas DE; Rubio Romero G; Maximiano Alonso C; Villa Guzmán JC; Puertas Álvarez JL; Chirivella González I; Méndez Vidal MJ; Juan Fita MJ; León-Mateos L; Lázaro Quintela M; García Domínguez R; Jurado García JM; Vélez de Mendizábal E; Lambea Sorrosal JJ; García Carbonero I; González del Alba A; Suárez Rodríguez C; Jiménez Gallego P; Meana García JA; García Marrero RD; Gajate Borau P; Santander Lobera C; Molins Palau C; López Brea M; Fernández Parra EM; Reig Torras O; Basterretxea Badiola L; Vázquez Estévez S; González Larriba JL
    Ann Oncol; 2016 Apr; 27(4):706-11. PubMed ID: 26658889
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A five-factor biomarker profile obtained week 4-12 of treatment for improved prognostication in metastatic renal cell carcinoma: Results from DARENCA study 2.
    Soerensen AV; Geertsen PF; Christensen IJ; Hermann GG; Jensen NV; Fode K; Petersen A; Sandin R; Donskov F
    Acta Oncol; 2016; 55(3):341-8. PubMed ID: 26449266
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Second line treatment of metastatic renal cell carcinoma: The Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients.
    Levy A; Menard J; Albiges L; Loriot Y; Di Palma M; Fizazi K; Escudier B
    Eur J Cancer; 2013 May; 49(8):1898-904. PubMed ID: 23490648
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.
    Di Lorenzo G; Buonerba C; Federico P; Rescigno P; Milella M; Ortega C; Aieta M; D'Aniello C; Longo N; Felici A; Ruggeri EM; Palmieri G; Imbimbo C; Aglietta M; De Placido S; Mirone V
    Eur Urol; 2010 Dec; 58(6):906-11. PubMed ID: 20884115
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Association between sarcopenia based on psoas muscle index and the response to nivolumab in metastatic renal cell carcinoma: A retrospective study.
    Ueki H; Hara T; Okamura Y; Bando Y; Terakawa T; Furukawa J; Harada K; Nakano Y; Fujisawa M
    Investig Clin Urol; 2022 Jul; 63(4):415-424. PubMed ID: 35796138
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis.
    Escudier B; Molinie V; Bracarda S; Maroto P; Szczylik C; Nathan P; Negrier S; Weiss C; Porta C; Grünwald V; Albiges L
    Eur J Cancer; 2016 Dec; 69():226-235. PubMed ID: 27680407
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Experience with everolimus therapy for patients with metastatic renal cancer in Hungary].
    Maráz A; Bodoky G; Dank M; Géczi L; Kahán Z; Mangel L; Révész J; Szűcs M
    Magy Onkol; 2014 Mar; 58(1):4-9. PubMed ID: 24712001
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma.
    Iacovelli R; Lanoy E; Albiges L; Escudier B
    BJU Int; 2012 Dec; 110(11):1747-53. PubMed ID: 23106948
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Body Composition in Relation to Clinical Outcomes in Renal Cell Cancer: A Systematic Review and Meta-analysis.
    Vrieling A; Kampman E; Knijnenburg NC; Mulders PF; Sedelaar JPM; Baracos VE; Kiemeney LA
    Eur Urol Focus; 2018 Apr; 4(3):420-434. PubMed ID: 28753824
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC Criteria in Patients With Metastatic Renal Cell Carcinoma: A Validation Study.
    Massari F; Di Nunno V; Guida A; Costa Silva CA; Derosa L; Mollica V; Colomba E; Brandi G; Albiges L
    Clin Genitourin Cancer; 2021 Feb; 19(1):32-40. PubMed ID: 32694008
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Factors Influencing Overall Survival for Patients With Metastatic Clear-Cell Renal-Cell Carcinoma in Daily Practice.
    Thiery-Vuillemin A; Cholley T; Calcagno F; Hugues M; Maurina T; Limat S; Nguyen Tan Hon T; Almotlak H; Mouillet G; Nerich V
    Clin Genitourin Cancer; 2018 Apr; 16(2):e297-e305. PubMed ID: 29066073
    [TBL] [Abstract][Full Text] [Related]  

  • 60. External validation of the systemic immune-inflammation index as a prognostic factor in metastatic renal cell carcinoma and its implementation within the international metastatic renal cell carcinoma database consortium model.
    Chrom P; Zolnierek J; Bodnar L; Stec R; Szczylik C
    Int J Clin Oncol; 2019 May; 24(5):526-532. PubMed ID: 30604160
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.